Join our daily newsletter At The Bell to receive exclusive market insights
The Chinese Food and Drug Administration has approved CardieX’s Oscar 2 blood pressure monitor. With more than 12 percent of annual adult deaths resulting from hypertension, this device will be used by over 20,000 physicians to detect, diagnose, monitor and manage it.
It will measure central aortic blood pressure and conduct a central pressure waveform analysis. Patients will be able to monitor blood pressure over a 24-hour period at home with results being sent to doctors and then discussed.
The monitor features SphygmoCor technology, supplied by CardieX’s subsidiary AtCor, and is manufactured by SunTech Medical.
CardieX is also looking to create additional partnerships for in-home vital sign monitoring, home-use blood pressure monitoring, digital health, and smart health wearables.
CardieX CEO Craig Cooper hopes that this partnership will benefit those experiencing hypertension.
“This collaboration highlights the way CardieX aims to develop, grow and expand into the largest and most significant health market in the world,” he said.
Earning revenue of more than $USD50 million per annum this is expected to roll out in China in the second half of 2019.
Please find the announcement here
Chart image: https://hotcopper.com.au/data/pricesensitive/charts/cdx_asx.png
